|
1
|
Mohammadi M and Hedayati M: A brief review
on the molecular basis of medullary thyroid carcinoma. Cell J.
18:485–492. 2017.PubMed/NCBI
|
|
2
|
Figlioli G, Landi S, Romei C, Elisei R and
Gemignani F: Medullary thyroid carcinoma (MTC) and RET
proto-oncogene: Mutation spectrum in the familial cases and a
meta-analysis of studies on the sporadic form. Mutat Res.
752:36–44. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sippel RS, Kunnimalaiyaan M and Chen H:
Current management of medullary thyroid cancer. Oncologist.
13:539–547. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Milling RV, Grimm D, Krüger M, Grosse J,
Kopp S, Bauer J, Infanger M and Wehland M: Pazopanib, cabozantinib,
and vandetanib in the treatment of progressive medullary
thyroidcancer with a special focus on the adverse effects on
hypertension. Int J Mol Sci. 19(pii): E32582018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fagin JA and Wells SA Jr: Biologic and
Clinical perspectives on thyroid cancer. N Engl J Med.
375:1054–1067. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
American Thyroid Association Guidelines
Task Force, ; Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF,
Gharib H, Moley JF, Pacini F, Ringel MD, Schlumberger M and Wells
SA Jr: Medullary thyroid cancer: Management guidelines of the
American Thyroid Association. Thyroid. 19:565–612. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Agrawal N, Jiao Y, Sausen M, Leary R,
Bettegowda C, Roberts NJ, Bhan S, Ho AS, Khan Z, Bishop J, et al:
Exomic sequencing of medullary thyroid cancer reveals dominant and
mutually exclusive oncogenic mutations in RET and RAS. J Clin
Endocrinol Metab. 98:E364–E369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
A T, F S, G P and M B: Genetic alterations
in medullary thyroid cancer: Diagnostic and prognostic markers.
Curr Genomics. 12:618–625. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Elisei R, Cosci B, Romei C, Bottici V,
Renzini G, Molinaro E, Agate L, Vivaldi A, Faviana P, Basolo F, et
al: Prognostic significance of somatic RET oncogene mutations in
sporadic medullary thyroid cancer: A 10-year follow-up study. J
Clin Endocrinol Metab. 93:682–687. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pishkari S, Paryan M, Hashemi M, Baldini E
and Mohammadi-Yeganeh S: The role of microRNAs in different types
of thyroid carcinoma: A comprehensive analysis to find new miRNA
supplementary therapies. J Endocrinol Invest. 41:269–283. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shabani N, Razaviyan J, Paryan M, Tavangar
SM, Azizi F, Mohammadi-Yeganeh S and Hedayati M: Evaluation of
miRNAs expression in medullary thyroid carcinoma tissue samples:
miR-34a and miR-144 as promising overexpressed markers in MTC. Hum
Pathol. 79:212–221. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abraham D, Jackson N, Gundara JS, Zhao J,
Gill AJ, Delbridge L, Robinson BG and Sidhu SB: MicroRNA profiling
of sporadic and hereditary medullary thyroid cancer identifies
predictors of nodal metastasis, prognosis, and potential
therapeutic targets. Clin Cancer Res. 17:4772–4781. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Romeo P, Colombo C, Granata R, Calareso G,
Gualeni AV, Dugo M, De Cecco L, Rizzetti MG, Zanframundo A, Aiello
A, et al: Circulating miR-375 as a novel prognostic marker for
metastatic medullary thyroid cancer patients. Endocr Relat Cancer.
25:217–231. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lassalle S, Zangari J, Popa A, Ilie M,
Hofman V, Long E, Patey M, Tissier F, Belléannée G, Trouette H, et
al: MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of
vandetanib. Oncotarget. 7:30461–30478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Giordano TJ, Kuick R, Thomas DG, Misek DE,
Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al:
Molecular classification of papillary thyroid carcinoma: Distinct
BRAF, RAS, and RET/PTC mutation-specific gene expression profiles
discovered by DNA microarray analysis. Oncogene. 24:6646–6656.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Giordano TJ, Au AY, Kuick R, Thomas DG,
Rhodes DR, Wilhelm KG Jr, Vinco M, Misek DE, Sanders D, Zhu Z, et
al: Delineation, functional validation, and bioinformatic
evaluation of gene expression in thyroid follicular carcinomas with
the PAX8-PPARG translocation. Clin Cancer Res. 12:1983–1993. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li D, Hao X and Song Y: Identification of
the key MicroRNAs and the miRNA-mRNA regulatory pathways in
prostate cancer by bioinformatics methods. Biomed Res Int.
2018:62041282018.PubMed/NCBI
|
|
20
|
Mou T, Zhu D, Wei X, Li T, Zheng D, Pu J,
Guo Z and Wu Z: Identification and interaction analysis of key
genes and microRNAs in hepatocellular carcinoma by bioinformatics
analysis. World J Surg Oncol. 15:632017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li J, Qin Y and Zhang H: Identification of
key miRNA-gene pairs in chronic lymphocytic leukemia through
integrated analysis of mRNA and miRNA microarray. Oncol Lett.
15:361–367. 2018.PubMed/NCBI
|
|
22
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
starBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res 42 (Database Issue). D92–D97. 2014. View Article : Google Scholar
|
|
23
|
Kanehisa M, Sato Y, Kawashima M, Furumichi
M and Tanabe M: KEGG as a reference resource for gene and protein
annotation. Nucleic Acids Res. 44(D1): D457–D462. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tripathi S, Pohl MO, Zhou Y,
Rodriguez-Frandsen A, Wang G, Stein DA, Moulton HM, DeJesus P, Che
J, Mulder LC, et al: Meta- and orthogonal integration of influenza
‘OMICs’ data defines a role for UBR4 in virus budding. Cell Host
Microbe. 18:723–735. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xia J, Benner MJ and Hancock RE:
NetworkAnalyst-integrative approaches for protein-protein
interaction network analysis and visual exploration. Nucleic Acids
Res 42 (Web Server Issue). W167–W174. 2014. View Article : Google Scholar
|
|
26
|
Xia J, Gill E and Hancock RE:
NetworkAnalyst for statistical, visual and network-based
meta-analysis of gene expression data. Nat Protoc. 10:823–844.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang J, Lu M, Qiu C and Cui Q: TransmiR: A
transcription factor-microRNA regulation database. Nucleic Acids
Res 38 (Database Issue). D119–D122. 2010. View Article : Google Scholar
|
|
28
|
Tong Z, Cui Q, Wang J and Zhou Y: TransmiR
v2.0: An updated transcription factor-microRNA regulation database.
Nucleic Acids Res. 47(D1): D253–D258. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Scollo C, Baudin E, Travagli JP, Caillou
B, Bellon N, Leboulleux S and Schlumberger M: Rationale for central
and bilateral lymph node dissection in sporadic and hereditary
medullary thyroid cancer. J Clin Endocrinol Metab. 88:2070–2075.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Griebeler ML, Gharib H and Thompson GB:
Medullary thyroid carcinoma. Endocr Pract. 19:703–711. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schlumberger M, Carlomagno F, Baudin E,
Bidart JM and Santoro M: New therapeutic approaches to treat
medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab.
4:22–32. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Conzo G, Polistena A, Calò PG, Bononi P,
Gambardella C, Mauriello C, Tartaglia E, Avenia S, Sanguinetti A,
Medas F, et al: Efficacy of combined treatment for anaplastic
thyroid carcinoma: Results of a multinstitutional retrospective
analysis. Int J Surg. 12 (Suppl 1):S178–S182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Conzo G, Avenia N, Ansaldo GL, Calò P, De
Palma M, Dobrinja C, Docimo G, Gambardella C, Grasso M, Lombardi
CP, et al: Surgical treatment of thyroid follicular neoplasms:
Results of a retrospective analysis of a large clinical series.
Endocrine. 55:530–538. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Shi L, Zhao SM, Luo Y, Zhang AW, Wei LH,
Xie ZY, Li YY and Ma W: MiR-375: A prospective regulator in
medullary thyroid cancer based on microarray data and
bioinformatics analyses. Pathol Res Pract. 213:1344–1354. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Galuppini F, Bertazza L, Barollo S,
Cavedon E, Rugge M, Guzzardo V, Sacchi D, Watutantrige-Fernando S,
Vianello F, Mian C and Pennelli G: MiR-375 and YAP1 expression
profiling in medullary thyroid carcinoma and their correlation with
clinical-pathological features and outcome. Virchows Arch.
47:651–658. 2017. View Article : Google Scholar
|
|
36
|
Hudson J, Duncavage E, Tamburrino A,
Salerno P, Xi L, Raffeld M, Moley J and Chernock RD: Overexpression
of miR-10a and miR-375 and downregulation of YAP1 in medullary
thyroid carcinoma. Exp Mol Pathol. 95:62–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nusse R and Clevers H: Wnt/β-catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tai D, Wells K, Arcaroli J, Vanderbilt C,
Aisner DL, Messersmith WA and Lieu CH: Targeting the WNT signaling
pathway in cancer therapeutics. Oncologist. 20:1189–1198. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Maliszewska A, Leandro-Garcia LJ,
Castelblanco E, Macià A, de Cubas A, Goméz-López G, Inglada-Pérez
L, Álvarez-Escolá C, De la Vega L, Letón R, et al: Differential
gene expression of medullary thyroid carcinoma reveals specific
markers associated with genetic conditions. Am J Pathol.
182:350–362. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Colak S and Ten Dijke P: Targeting TGF-β
signaling in cancer. Trends Cancer. 3:56–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Santarpia L, Calin GA, Adam L, Ye L, Fusco
A, Giunti S, Thaller C, Paladini L, Zhang X, Jimenez C, et al: A
miRNA signature associated with human metastatic medullary thyroid
carcinoma. Endocr Relat Cancer. 20:809–823. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jeong D, Park S, Kim H, Kim CJ, Ahn TS,
Bae SB, Kim HJ, Kim TH, Im J, Lee MS, et al: RhoA is associated
with invasion and poor prognosis in colorectal cancer. Int J Oncol.
48:714–722. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Zhang GY, Yang WH and Chen Z: Upregulated
STAT3 and RhoA signaling in colorectal cancer (CRC) regulate the
invasion and migration of CRC cells. Eur Rev Med Pharmacol Sci.
20:2028–2037. 2016.PubMed/NCBI
|
|
46
|
Takahashi C, Contreras B, Iwanaga T,
Takegami Y, Bakker A, Bronson RT, Noda M, Loda M, Hunt JL and Ewen
ME: Nras loss induces metastatic conversion of Rb1-deficient
neuroendocrine thyroid tumor. Nat Genet. 38:118–123. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu Z, Zhang J, Gao J and Li Y:
MicroRNA-4728 mediated regulation of MAPK oncogenic signaling in
papillary thyroid carcinoma. Saudi J Biol Sci. 25:986–990. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pan J, Zhang L, Xu S, Cheng X, Yu H, Bao J
and Lu R: Induction of apoptosis in human
papillary-thyroid-carcinoma BCPAP cells by diallyl trisulfide
through activation of the MAPK signaling pathway. J Agric Food
Chem. 66:5871–5878. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chang YS, Chang CC, Huang HY, Lin CY, Yeh
KT and Chang JG: Detection of molecular alterations in taiwanese
patients with medullary thyroid cancer using whole-exome
sequencing. Endocr Pathol. 29:324–331. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Teng F, Xu Z, Chen J, Zheng G, Zheng G, Lv
H, Wang Y, Wang L and Cheng X: DUSP1 induces apatinib resistance by
activating the MAPK pathway in gastric cancer. Oncol Rep.
40:1203–1222. 2018.PubMed/NCBI
|
|
51
|
Fang J, Ye Z, Gu F, Yan M, Lin Q, Lin J,
Wang Z, Xu Y and Wang Y: DUSP1 enhances the chemoresistance of
gallbladder cancer via the modulation of the p38 pathway and DNA
damage/repair system. Oncol Lett. 16:1869–1875. 2018.PubMed/NCBI
|
|
52
|
Zhang Y, Zhang Y, Chen M, Liu C and Xiang
C: DUSP1 is involved in the progression of small cell carcinoma of
the prostate. Saudi J Biol Sci. 25:858–862. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang Y, Kuramitsu Y, Ueno T, Suzuki N,
Yoshino S, Iizuka N, Zhang X, Oka M and Nakamura K: Differential
expression of up-regulated cofilin-1 and down-regulated cofilin-2
characteristic of pancreatic cancer tissues. Oncol Rep.
26:1595–1599. 2011.PubMed/NCBI
|
|
54
|
Yu BB, Lin GX, Li L, Qu S, Liang ZG, Chen
KH, Zhou L, Lu QT, Sun YC and Zhu XD: Cofilin-2 acts as a marker
for predicting radiotherapy response and is a potential therapeutic
target in nasopharyngeal carcinoma. Med Sci Monit. 24:2317–2329.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Liu J, Li H, Shen S, Sun L, Yuan Y and
Xing C: Alternative splicing events implicated in carcinogenesis
and prognosis of colorectal cancer. J Cancer. 9:1754–1764. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Khiroya H, Moore JS, Ahmad N, Kay J,
Woolnough K, Langman G, Ismail I, Naidu B, Tselepis C and Turner
AM: IRP2 as a potential modulator of cell proliferation, apoptosis
and prognosis in nonsmall cell lung cancer. Eur Respir J. 49(pii):
16007112017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Siqingaow a, Sekar S, Gopalakrishnan V and
Taghibiglou C: Sterol regulatory element-binding protein 1
inhibitors decrease pancreatic cancer cell viability and
proliferation. Biochem Biophys Res Commun. 488:136–140. 2017.
View Article : Google Scholar : PubMed/NCBI
|
